Join us at Antibody engineering and Therapeutics 2023: Dec 13-16
Join us at Antibody engineering and Therapeutics 2023 in San Diego, CA from December 13-16! Meet us at Booth 208, and at our 3 posters, to learn more about our antibody discovery platforms, services and other solutions to help support your research projects and pipeline. Posters: Discovery of RenNano®-derived human heavy-chain-only TFR1 antibodies that can […]
Biocytogen Secures U.S. Patent for Key Technology of the Fully Human Antibody Mouse (RenMab) Platform
December 5, 2023
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) is pleased to announce that the company has been granted a patent from the United States Patent and Trademark Office (No. US-11730151-B2) for the key technology of RenMabTM mice, a proprietary fully human antibody mouse platform used to accelerate therapeutic antibody discovery. This milestone follows the issuance […]
CNS Drug Delivery Summit 2023: Biocytogen to Showcase Payload Brain Delivery of Fully Human TFR1 HCAbs
Biocytogen’s antibody BD & Licensing team will present a poster entitled “Discovery of RenNano®-derived human heavy-chain-only TFR1 antibodies that can efficiently cross the blood-brain barrier and deliver drug payloads” at the upcoming 5th annual CNS Drug Delivery Summit, held in Boston, US from December 5-7, 2023. TFR1 heavy-chain-only antibodies (HCAbs) discovered from Biocytogen’s proprietary fully […]
Join us at Cell Bio 2023 by American Society for Cell Biology: Dec 2-6
Join us at Cell Bio 2023 organized by American Society for Cell Biology from Dec 2-6 in Boston! Meet us at Booth 703 and learn more about our custom model generation services and pharmacology services to support your therapeutic discovery and preclinical validation. Attend the meeting Talk to us at booth 703! Cell Bio 2023, […]
$1,000 OFF Any Gene Targeting Project
November 20, 2023
Get started on your gene editing project as the year comes to a close! As the holiday season approaches, we are thrilled to offer you a $1,000 credit that can be applied to your next gene targeting project. *Limited time only. Must receive PO by December 31, 2023. Our Platform Our Extreme Genome Editing (EGETM) […]
Check out our poster at 15th Annual PEGS Europe: Nov 14-16
Join us at the 15th Annual PEGS Europe in Lisbon, Portugal from Nov 14-16! Don’t miss our poster session featuring Anti-TROP2 x EGFR Bispecific ADC below: Poster Number: B026 Poster Title: DM001, a Novel Anti-TROP2 x EGFR Bispecific ADC (BsADC) with a Novel Topoisomerase I Inhibitor Payload, Demonstrates Potent Anti-Tumor Activity in Preclinical Models and […]
SITC 2023 Highlights: Biocytogen’s Novel Assets and Products
The Biocytogen team concluded a successful SITC 2023 event, after presenting 9 drug asset posters, 7 genetically engineered mouse model posters, and connecting with current and prospective clients at booth 223. Summarized below are the highlights presented from each product/research area: Bispecific ADC Assets Advantages of BsADCs Biocytogen’s R&D team developed a series of fully […]
Join us at the Neuroscience 2023: Nov 11-15
Join us at Neuroscience 2023 in Washington, D.C. from Nov 11-15! Visit booth #637 to chat with our team and learn about our preclinical animal models and state-of-the-art services, ranging from antibody discovery to pharmacology evaluation services. Attend the meeting Talk to us at booth 637! Scientists from around the world will congregate at Neuroscience […]
Discover the Future of Antibody/TCR-based Therapeutics: Meet Biocytogen’s Licensing Team at BIO-EUROPE 2023!
Biocytogen will be exhibiting and hosting 1-on-1 meetings at BIO-EUROPE 2023, taking place from November 6-8, 2023 in Munich, Germany. Biocytogen is thrilled to be part of this premier event, showcasing our latest innovations in clinical and preclinical therapeutic asset discovery and development. Here’s how to connect with us at the event: Booth #60: Connect […]
Webinar: Generation of TCR-mimic antibodies targeting intracellular proteins to expand the druggable target repertoire for anti-tumor therapies
Our webinar “Generation of TCR-mimic antibodies targeting intracellular proteins to expand the druggable target repertoire for anti-tumor therapies” was live at 12:00 PM EST on Nov 14th, 2023. About the webinar: Traditional antibody therapy has been limited to extracellular tumor targets; however, many oncogenic and tumor-associated proteins are intracellular. One strategy to overcome this limitation is […]
